Abstract: Atrial fibrillation (AF) is the most common sustained heart rhythm disorder and is associated with substantial morbidity and mortality. Current treatment options for AF have significant limitations. Basic research has provided information on mechanisms relevant to the management of AF and promises to contribute significantly to future advances, yet many important translational challenges remain. Here, we analyze the therapeutic limitations for which improvement is needed, consider the translational opportunities presented by recent scientific and technological developments, and attempt to look into the future of where these may lead. We first review the limitations of current AF management, with a focus on rhythm control therapy. These include arrhythmia complications, progression to advanced treatment-resistant forms, insufficient effectiveness of available therapeutic options, adverse consequences of therapy, and difficulties in new therapeutic development. The translational challenges in addressing these shortcomings are then addressed, including (1) defining actionable patient-specific arrhythmia mechanisms to enable personalized therapy; (2) identifying and treating key dynamic modulators controlling AF initiation and progression; (3) achieving atrial-restricted targeting of specific molecular arrhythmia mechanisms; and (4) clarifying the response of the substrate to interventions. For each of these, we describe the translational goal and the opportunities created by recent advances in cardiac imaging, computational modeling, rhythm monitoring, ablation technology, and preclinical studies in human samples and animal models. Finally, we consider the prospects for future solutions that might appreciably improve our ability to understand and manage the arrhythmia over the years to come. (Circ Res. 2018;122:752-773.
A trial fibrillation (AF) is an important and growing clinical problem 1 with a lifetime risk, governed by both clinical and genetic factors, averaging 37% overall. 2 AF engenders a substantial burden in terms of costs, morbidity, and mortality. There are major limitations to presently available treatment options. 3 Basic research has played a role in improving the management of AF and promises to contribute to future advances. 4 Here, we aim to review the limitations of presently available AF management and to present an analysis of selected translational challenges, the resolution of which might appreciably improve our ability to handle the arrhythmia.
Problems With Presently Available AF Management
There are 2 general approaches to managing AF: (1) controlling the ventricular response rate without attempting to terminate or prevent AF (rate control); and (2) attempting to obtain and maintain sinus rhythm (rhythm control). Although large-scale randomized trials have not demonstrated superiority of rhythm over rate control, 5, 6 there is widespread belief that the absence of benefit from more physiological rhythm control is because of the limited efficacy and adverse effects of sinus rhythm maintaining antiarrhythmic drugs (AADs). Indeed, recent randomized studies comparing rhythm control (with catheter ablation) to rate control have begun to show significant improvements in hard outcomes (eg, CAMERA-MRI 7 ). Therefore, we will focus primarily on translational approaches relating to the improvement of AF rhythm control and will not deal with the broader issue of rate control, nor with the translational science of atrial thrombosis and thromboembolism. Table 1 lists some of the major limitations and challenges of presently available AF management.
Complications of AF
The complications directly caused by AF are difficult to distinguish from those because of associated cardiac pathology. However, the arrhythmia continues to be associated with a high rate of adverse events. For example, the mortality rate in patients with incident AF >65 years in a Medicare database was 19.5% within 1 year after AF presentation and ≈50% at 5 years. 8 Other complications at 5 years included heart failure (HF) in 13.7%, stroke in 7.1%, and gastrointestinal hemorrhage in 5.7%. Outcomes of patients who developed AF as a secondary consequence of some primary inciting condition, including cardiothoracic surgery in 30% of cases, infection in 23%, noncardiothoracic surgery in 20%, and myocardial infarction in 18%, were investigated in the Framingham Heart Study. 9 Such secondary AF cases are generally thought to have a different natural history because they are due to a reversible acute cause and are often not treated with anticoagulants or other therapies targeted to primary AF. Perhaps surprisingly, AF recurrence rates (42% at 5 years) were only slightly less than for patients with primary AF (59% at 5 years) in the same database. Moreover, the stroke risk in secondary AF cases was high (occurring in ≈20% of cases) and not significantly different from those in primary AF.
AF Progression
AF is classified as paroxysmal if it terminates (spontaneously or with medical intervention) within 7 days, persistent if it lasts beyond 7 days, and long-standing persistent if it continues for >1 year. 10 The response of AF to therapeutic interventions is closely related to the form of AF, with progression from paroxysmal to persistent and to long-standing persistent AF producing increasing resistance to the restoration and maintenance of sinus rhythm. 1, 11 The frequency with which AF progresses from paroxysmal to more advanced forms varies among studies, but in a review of 17 registry analyses, a mean progression rate of ≈5% per year was noted. 12 Progression is not inevitable, and its occurrence depends on patient characteristics, such as the presence and severity of cardiovascular disease, the presence of comorbidities/risk factors, such as hypertension, obesity, diabetes mellitus, sleep apnea, cigarette smoking, excess alcohol consumption etc, and genetic determinants. Nevertheless, AF progression is widely recognized to be common and clinically undesirable. 13 
Insufficient Effectiveness of Therapeutic Options
Currently available treatment options all have limited effectiveness. AADs have moderate efficacy, reducing AF recurrence rates after elective cardioversion by 30% to 81%. 14 Numerous studies have shown ablation approaches to be much more effective than AADs; a meta-analysis of 46 studies revealed a 68% lower risk of AF recurrence with catheter ablation compared with medical therapy. 15 However, the vast majority of these studies were conducted in patients who had already proven to be resistant to AADs, which clearly biases the outcome against drug therapy. In trials of treatment initiated in patients with AF not selected for prior therapeutic responses, the differences in success between ablation and AAD therapy are much less striking. The RAAFT-2 (Radiofrequency Ablation vs AADs as First-line Treatment of paroxysmal AF) trial showed a modest difference between ablation and AAD therapy outcomes, with a 72% recurrence rate for AADs versus 55% for ablation (P=0.02). 16 The MANTRA-PAF trial showed no significant differences in AF burden between ablation and AAD groups up to 18 months, with a lower AF burden with ablation at 24 months (9% versus 18%; P<0.01). 17 The recurrence rates after AF ablation are substantial. When assessed with rigorous criteria in randomized trials, AF recurrence rates for the most responsive form, paroxysmal AF, are ≈40% to 60% within 1 to 1.5 years. 18, 19 Furthermore, even after initially-successful procedures, long-term recurrences are frequent, 20 likely because of underlying disease progression.
Adverse Consequences of Therapy
AADs are associated with a wide range of potential adverse effects. A recent Cochrane collaboration analysis examined outcomes in randomized, blinded trials of AADs for sinus rhythm maintenance after cardioversion. 14 Overall mortality tended to be higher with AADs, but only sotalol and class IA agents (as a group) showed a significant increase. Almost all drugs had a higher withdrawal rate for adverse events than control, and almost all drugs showed significant proarrhythmic potential. Only amiodarone (which showed a statistically nonsignificant proarrhythmic tendency) and propafenone were not associated with significant increases in proarrhythmic events versus control. In a 2014 meta-analysis, catheter ablation of AF was associated with almost twice as many major adverse events as AAD therapy. 21 Another meta-analysis indicated major complication rates of ≈3.5% in randomized controlled trials of catheter ablation and 5.4% in registry data. 22 Major complications included cardiac tamponade (0.9%-2.0%), stroke/transient ischemic attack (1.2%-0.7%), vascular access complications like hemorrhage and vascular damage (1.3%-2.4%), and inhospital death (0.3%-0.4%). Clearly, catheter ablation is not a benign procedure. Further information on AF ablation safety is likely to emerge from registries, like the Safety of Atrial Fibrillation Ablation Registry Initiative.
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Practical Challenges to New Therapeutic Development A variety of practical issues affect the development of new therapeutic approaches to AF. Regulatory costs make the introduction of new drugs, particularly for cardiac arrhythmia indications, extremely expensive; a price tag of $5 billion has been estimated for each new drug reaching the market. 24 However, AF is an extremely common and costly clinical problem, so the market for effective new treatments is considerable. Regulatory procedures for nonpharmacological treatments are generally less demanding than those for pharmaceuticals, which may have contributed to their rapid development over the past decades. Although these less restrictive regulatory requirements have allowed more rapid development and application of nonpharmacological approaches, they may also have contributed to the relative lack of randomized clinical trial assessments of the effects of such approaches on hard clinical morbidity/mortality end points.
A final challenge to innovative therapy may be the human tendency to have difficulties in identifying new ideas that do not fit into well-established modes of thought. Our thinking about AF mechanisms largely parallels concepts that were first put forward a hundred years ago. 25 That reality may reflect the clairvoyance of early investigators, but it may also reflect our challenges in recognizing observations that deviate from expectations based on these classical notions and that may be the key to paradigm-shifting discoveries. There may in fact be no important new mechanisms to be discovered, but if such unrecognized mechanisms do exist, it is important to keep our minds open to their discovery. In addition, the involvement of multidisciplinary reflection groups may help to bring new perspectives and fresh approaches to bear.
Translational Challenges
In this section, we will discuss specific challenges in AF management for which the clinical application of new basic science and technological advances has the potential to substantially improve medical care. For each of these, we will consider the translational goal and rationale, the opportunities created by recent advances and ongoing work, and the prospects for future solutions via translational research.
Defining Actionable Patient-Specific Arrhythmia Mechanisms
Translational Goal and Rationale Current guidelines suggest therapeutic selection based principally on the type of AF (paroxysmal versus persistent versus long-standing persistent forms). 26, 27 However, the targeting of individual patient arrhythmia mechanisms would seem more likely to provide effective personalized therapies, based on recent basic science advances. 28 Conceptually, 2 main mechanisms drive AF onset and maintenance: ectopic foci, mainly arising from the pulmonary veins in paroxysmal AF, 29 and reentry, which is also particularly likely to occur at or near the pulmonary veins 30 ( Figure 1 ). Ectopic activity can maintain AF when ≥1 foci fire repetitively at a high frequency and can act as a trigger initiating reentry, the major AF-maintaining mechanism, via a vulnerable substrate characterized by electric or structural abnormalities. 1, 11 Although ectopic activity in the form of atrial premature complexes seems to initiate AF in >95% of cases, 31 premature excitation is not always essential for reentry initiation: spatiotemporal action potential instabilities like spatially discordant alternans can cause regional block and reentry in the absence of ectopic activity. A large number of preclinical studies have helped to clarify some of the cellular and molecular mechanisms of atrial arrhythmogenesis. Ectopic activity results primarily from abnormal automaticity or triggered activity because of early afterdepolarization and delayed afterdepolarization (DAD).
11 Both animal models and in vitro human studies have identified a major role for Ca 2+ -handling abnormalities, mediated primarily by dysfunction of the sarcoplasmic reticulum (SR) Ca 2+ -release channel (type-2 ryanodine receptor [RyR2]) in the genesis of DADs and triggered activity. 11, 32 Reentry depends on the interaction between effective refractory period (ERP), conduction velocity and local depolarization properties of the propagating wavefront (the source) on one hand, and the tissue ahead of the wavefront and in the rotor core (the sink). 33, 34 When primary rotors encounter functional obstacles, wavebreaks generate secondary rotors that may be annihilated or may persist as generators of arrhythmic activity. It is important to recognize that rotor activity need not be stable in space and time and that AF can be maintained by evanescent rotors provided that the rate of secondary rotor generation exceeds the rate of rotor annihilation. 35 Fibrosis is an important stabilizer for AF-maintaining reentrant circuits/rotors by promoting conduction block and slow, heterogeneous conduction. [36] [37] [38] Macroscopic reentry around large anatomic obstacles is often involved in atrial flutter, whereas smaller anatomic obstacles as well as functional barriers may anchor rotors involved in AF maintenance. 38 In addition, ERP shortening because of electric remodeling and left atrial (LA) enlargement also support reentry by decreasing rotor dimensions and increasing available space for reentrant circuits, respectively. 1, 34 In more advanced forms of AF, electric activity becomes increasingly complex with multiple concurrent reentry circuits and ectopic foci (Figure 1) .
Although a great deal of information has been obtained about AF mechanisms based on animal models, in vitro studies, and in vivo human work, 1, 11, [37] [38] [39] the application of this information to provide patient-specific therapy has lagged far behind. Indeed, although a large amount of fundamental science information has been obtained about the biological determinants of AF mechanisms, the clinical approach to treating most patients with AF remains traditional. 28, 40 The principal factors determining clinical decision making are the presence or absence of symptoms, whether the AF is paroxysmal or persistent, and if persistent how long it has been present ( although the precise determination of AF persistence is often clinically challenging). Arrhythmia mechanisms are not generally evaluated on an individual patient basis and are not specifically targeted therapeutically. Mechanistic targeting has the potential to sharpen and improve therapeutic choices; here, we consider the prospects for achieving the first necessary step, identifying the mechanistic substrate in individual cases.
Opportunities Created by Recent Advances
Studies in atrial samples obtained from patients undergoing open-heart surgery have made it clear that there is a large diversity in AF-predisposing mechanisms. For example, despite the common phenotypic presentation of increased spontaneous SR Ca 2+ -release events in patients with paroxysmal and long-standing persistent AF, the underlying molecular mechanisms are distinct. [41] [42] [43] Patients with paroxysmal AF have increased SR Ca 2+ load and RyR2 dysfunction in the absence of RyR2 phosphorylation changes or indices of electric remodeling, whereas patients with long-standing persistent AF have unaltered SR Ca 2+ load, phosphorylation-dependent RyR2 dysfunction, and pronounced electric remodeling, notably reentry-promoting ERP shortening. 41, 43 Similarly, there are notable differences in atrial electric remodeling in the absence or presence of left ventricular dysfunction. [44] [45] [46] [47] This information can at present only be obtained from a rather small patient population undergoing open-heart surgery, and almost all studies rely on samples from the right atrial appendage (raising questions about direct applicability to other atrial regions critically involved in the arrhythmia). However, accumulating evidence also suggests an increasingly important role of the right atrium, with up to 50% of cases exhibiting drivers/rotors located in the right atrium, 48, 49 and the above findings do suggest that specific mechanism-based approaches might be necessary to tailor AF therapy to individual patients. More work is needed to confirm these observations, to assess underlying mechanisms and consequences, and to extend them to other regions of the atria.
Besides mechanistic advances at the molecular/cellular level, substantial progress has been made in atrial imaging, with the aim of providing noninvasive means to assess atrial electric and structural remodeling in individual patients. Late gadolinium enhancement (LGE)-cardiac magnetic resonance imaging (MRI) can provide topographical assessment and quantification of fibrotic lesions and other structural abnormalities (edema, amyloidosis, etc). Preablation LGE-MRI has shown promise in predicting responses to AF ablation. 50, 51 Alternatively, atrial fibrosis can be assessed indirectly with echocardiography, which is more readily available than MRI, via measurement of LA reservoir function and compliance during sinus rhythm. 52 Atrial strain can be assessed by tissue Doppler imaging or 2-dimensional speckle tracking: altered atrial strain and local strain heterogeneity are markers of atrial fibrosis. 53 In addition, an increased LA size provides a larger substrate for reentry, and LA enlargement is an important risk factor for AF recurrence. LA size can be assessed clinically with many techniques, including MRI, computed tomography, and echocardiography. Combined assessment of LA fibrosis using echocardiographic imaging of mural ultrasound reflectivity and LA size has been shown to improve the identification of patients with a high likelihood of successful ablation. 54 Directly screening the precise mechanisms underlying abnormal atrial electric activity, as opposed to the underlying atrial structural substrate, is another ongoing challenge. Detailed analyses of the properties of P-waves on the body surface ECG, reflecting atrial depolarization, provide information about the severity of atrial remodeling. Indeed, the maximal amplitude of P-waves, P-wave duration, and P-wave terminal force in lead V 1 , integrating P-wave duration and amplitude, are useful tools to screen for an atrial cardiomyopathy. 55 ,56 ECG-derived AF complexity parameters are predictive of AF termination and long-term success of catheter ablation in patients with persistent AF. 57 Body surface potential maps are expected to contain additional information because of the larger number of electrodes, allowing phase analysis of body surface potentials to localize reentrant drivers to the left or right atrium. 58, 59 Noninvasive atrial activation mapping (by ECG imaging, [ECGi] ) also has the potential to identify patient-specific AF mechanisms. This method uses a large number of body surface electrodes combined with a computed tomography scan to build up a 3-dimensional model of the spatial relationship of the electrodes to heart structures. 60 ECGi has highlighted significant interpatient and temporal variability in AF mechanisms 61 and may facilitate the development of personalized ablation strategies. 37 Finally, several recent invasive imaging methodologies providing unprecedented levels of detail have been used to characterize AF mechanisms and guide ablation therapy. For example, Narayan et al 39 developed an invasive method to highlight AF-maintaining sources (drivers), whether rotors or focal impulses, using a 64-pole basket catheter, which has been suggested to increase the efficacy of ablation of nonparoxysmal AF. This method, called focal impulse and rotor modulation (FIRM), uses a combination of multipolar basket catheter mapping and mathematical analyses to infer detailed activation pattern information. The reproducibility 62 and benefit 63 of these ablation strategies compared with standard pulmonary vein isolation remain topics of debate. Several randomized, prospective, controlled trials are currently ongoing to address this controversy. 34 Currently available mapping technologies still have several limitations that may influence reliable identification of patient-specific arrhythmia mechanisms. 59, 64, 65 For example, sequential point-bypoint mapping may fail to capture important dynamic changes in atrial electrophysiology, and noise, far-field effects, multicomponent signals, and large interelectrode distances can complicate the interpretation of electrograms and electrogram-derived maps. Phase mapping is a central tool in the analysis of rotors and offers various choices that influence the sensitivity and specificity of rotor detection. 34, 59, 66 Additional pre-processing may be necessary for some signals, which can add an additional layer of complexity and make it challenging to interpret and compare different mapping technologies. 58, 59, 65 Reconstruction of simulated electrophysiological patterns has provided insights into the ability to detect rotors with presently available methods, 59 but validation of electrophysiological mapping approaches against direct optical mapping in human hearts is largely missing although preliminary data are available for FIRM. 67 There are important discrepancies between the types of rotor activity noted in FIRM mapping (generally relatively stable in space and time) versus ECGi (typically short-lasting and localizing to the edge of fibrotic zones). Further work is needed to resolve these discrepancies, and improved in vivo mapping techniques are needed to accomplish this.
Atrial-specific biomarkers might provide a complementary approach to characterize the vulnerable substrate for AF. Blood-based biomarkers play a central role in the detection, classification, and therapy of acute coronary syndromes, providing a rapid noninvasive assessment of the extent of cardiac damage. Recent advances in high-sensitivity troponin assays have enabled the detection of extremely low levels of troponin, creating the opportunity to detect cardiac damage resulting from cardiovascular conditions other than discrete myocardial infarctions. 68 Currently available high-sensitivity troponin assays have modest utility in predicting new onset of AF and its adverse consequences (stroke, mortality), and similar results have been obtained for B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide. 68, 69 The use of biomarkers to refine stroke and bleeding risk estimation in patients with AF , for example, using the age, biomarkers, clinical characteristics risk scores, has recently received a class IIb recommendation in the European AF guidelines. 26 However, these biomarkers do not specifically reflect atrial damage, and relevant changes in these biomarkers produced by AF may be obscured by ventricular pathologies resulting from hypertension, coronary artery disease, and HF, which are common in patients with AF.
1 Furthermore, the relationship between these biomarkers and AF is largely associative, and their relevance for identifying individual mechanisms is unclear.
Prospects for Future Solutions
State-of-the-art imaging methodologies hold great promise to help identify patient-specific AF mechanisms. Detailed ex vivo optical mapping has been used increasingly and provides a bridge between molecular and in situ pathophysiological studies of AF mechanisms and between electrophysiological and structural properties. For example, ex vivo high-resolution optical mapping has confirmed the spatiotemporal characteristics of reentrant AF drivers observed with FIRM. 67 Adenosine-induced AF is maintained by reentrant drivers localized in lateral right atrial regions with the highest adenosine A1 receptor/GIRK4 expression, 49 and the complex atrial microstructure is responsible for epicardial-endocardial interactions that contribute to AF-maintaining intramural reentry. 70 Advances in in vivo molecular imaging might make it possible to visualize and quantify these electrophysiological determinants at molecular and cellular levels in a noninvasive manner, providing an opportunity to identify patient-specific fundamental arrhythmia mechanisms. Photoacoustic imaging, a method based on acoustic waves generated in response to the absorption of laser pulses, combines the high contrast of optical imaging with the high spatial resolution of ultrasound. 71, 72 This methodology can currently achieve a submillimeter resolution for penetration depths of several centimeters and is already used for in vivo imaging in animals, for example, for detection and molecular characterization of tumors and imaging of vascular plaques, although clinical applications are currently still limited. 71, 73, 74 Photoacoustic imaging has, for example, been used to noninvasively detect matrix metalloproteinase-2 and -9 activity in thyroid tumors in mice 75 ; these proteins are also upregulated in AF and have been implicated in atrial structural remodeling. 76 Photoacoustic imaging can be combined with different signaling compounds and targeting ligands to study various pathophysiological processes that are also relevant for AF. For example, photoacoustic probes based on polymer nanoparticles have been described for in vivo imaging of reactive oxygen species in mice. 74 Moreover, a Ca 2+ sensor for photoacoustic imaging has recently been developed and used to perform live imaging of Ca 2+ fluxes in genetically unmodified cells, heart organoids, and zebrafish larval brain, suggesting potential future applications for in vivo Ca 2+ imaging in the heart; either noninvasively or through catheter-based photoacoustic imaging, 77 which might also enable more atrial-specific detection ( Figure 2 ). However, this technology is still in early stages of development. Finally, recent work has shown the feasibility in animal models of monitoring mitochondrial function in vivo via resonance Raman spectroscopy to visualize alterations in cellular energetics that lead to cardiac arrest associated with myocardial ischemia. 78 This technology may eventually be applicable to the in vivo study of atrial metabolic alterations leading to AF occurrence or perpetuation.
Recent advances in computer modeling have raised the possibility of the clinical use of patient-specific computer models for risk assessment, identification of patient-specific mechanisms, and guidance of therapy. 79 In particular, these computer models may provide the missing link between structural information provided by imaging modalities and electrocardiographic information obtained from ECGs and noninvasive or invasive cardiac mapping studies. Given the success of pulmonary vein isolation in patients with paroxysmal AF, computational modeling has predominantly been applied to guide ablation in patients with persistent AF, under the assumption that the fixed fibrotic substrate in each individual enables AFmaintaining activity outside the pulmonary veins. Preablation MRI is used to develop a model with patient-specific anatomy and fibrosis-intensity distribution, and atrial electrophysiology is simulated using a computational model of the human atrial action potential, 80 potentially including differences in electrophysiological properties among different atrial regions. The models are then subjected to virtual programmed electric stimulation from different locations to assess the inducibility of AF in the absence or presence of different simulated interventions. Such models have been used to analyze mechanistic underpinnings of reentrant drivers 81 and (retrospectively) explore new strategies for personalizing atrial ablation procedures, 82, 83 highlighting their potential for clinical use. At present, these computational analyses may take several days for a single patient in highly experienced laboratories with access to state-of-the-art high-performance computing facilities. 79 More importantly, the resolution of current imaging modalities is insufficient to detect endomysial fibrosis in the epicardium, which may be critical for AF maintenance. 84 Similarly, in current versions, only the structural substrate is patient specific, whereas electrophysiological properties are determined with a generic model of human atrial electrophysiology, modified for the remodeled substrate based on several assumed changes. These limitations likely contribute to the relatively low complexity of AF patterns observed in simulations compared with invasive mapping studies. 85 In addition, recent detailed analyses indicate that a generic electrophysiological model combined with detailed anatomic structural information is not sufficient for patient-specific electroanatomical simulation and that the analyses need to be constrained by patient-specific electrophysiological action potential duration and conduction velocity properties to accurately identify rotor location. 85 Nonetheless, this approach is already being used, with some apparent degree of success, to guide AF ablation (Trayanova N, personal communication, 2017). Furthermore, it seems likely that advances in MRI (enabling more detailed simulation of structural remodeling), noninvasive ECGi (providing opportunities to personalize atrial electrophysiological properties), and computer hardware (reducing the time required for these simulations) will help to overcome these limitations in the near future. Advances in our understanding of the relationships between patient-specific ion current/ion channel protein profiles, functional consequences, and relevant noninvasively accessible electrophysiological indices may further help to improve patient-specific Figure 2 . Photoacoustic imaging to define patient-specific atrial fibrillation mechanisms. Photoacoustic imaging uses (1) a pulsed-wave laser beam to activate endogenous (eg, water molecules, lipids, collagen) or exogenous photoabsorbing molecules, producing (2) thermal vibrations that generate (3) acoustic waves, which can be detected and localized using (4) ultrasound. Integration of photoacoustic imaging in an electrophysiology catheter in combination with intracardiac echocardiography could be used to assess ablation lesions (through endogenous chromophores) and perform in vivo Ca 2+ imaging through novel cell-permeable photoacoustic Ca 2+ indicators. electrophysiological simulation. In selected patients, arrhythmia modeling with comprehensive computational simulations might thus eventually play a role in the preprocedural characterization of the optimal ablation strategy and perhaps in the prediction of the patient response to drug treatment.
There is clearly a need for improved imaging of the electrophysiological substrate in vivo. The commercial interest in attacking the AF ablation conundrum has spawned a range of new mapping technologies designed to obtain improved high-resolution imaging of cardiac activation. The Rhythmia technology relies on a multipolar basket catheter and computational analysis to derive atrial impulse propagation and has been applied to ablate atypical macroreentrant atrial flutters. 86 Another system in development (AcQMap) uses a novel dipole approach instead of classical electrogram methods, coupled to 48 local ultrasound transducers to obtain high-resolution structural information. This method has been applied to resolve long-standing (16 year) persistent AF by ablating 2 zones of localized rotational activity and the tricuspid isthmus in an initial test case. 87 ECGi has thus far been used in isolation pre-procedurally to help guide AF ablations 24 hours later. 37 It might be interesting in the future to combine the strengths of ECGi and advanced basket catheter technology to obtain improved atrial activation resolution to better define arrhythmia mechanisms and guide ablation.
Advances in genetic technology have led to the hope that genetic findings might prove to be a powerful tool for individualizing AF treatment. 88 Although rapid progress has been made in the field of AF genetics, the practical clinical applications remain limited. 89, 90 Preliminary clinical studies investigating the potential of pharmacogenetics-guided AAD therapy are currently ongoing (NCT02347111), suggesting a potential for future tailored therapy. The degree of clinical risk prediction possible based on genetic information has greatly increased with advances in genetic knowledge, 2 so it is possible that genetic risk prediction will become a standard component of AF management in the future. Likewise, alternative AF-related biomarkers (eg, based on tissue inhibitors of matrix metalloproteinases or other fibrosis-related markers, like suppression of tumorigenicity-2 and galectin-3) remain an active topic of research. [91] [92] [93] Identification of atrial-specific biomarkers may help to noninvasively stratify atrial remodeling or AF burden more reliably, although their relevance to identify patient-specific mechanisms and their additive benefit on top of established markers and risk models remain uncertain at present. 93 
Identifying and Targeting Key Dynamic Modulators
Translational Goal and Rationale AF is a highly dynamic condition, often involving episodes of sinus rhythm punctuated by periods of arrhythmia. In many patients, AF is progressive, with more frequent and longer episodes that become increasingly difficult to terminate, and a rate of progression that is highly variable from patient to patient. 12 The onset and termination of AF episodes are likely related to dynamic factors that govern their occurrence. A better understanding of the key dynamic modulators promoting AF initiation and termination might provide new opportunities for effective long-term AF management.
Both the trigger and substrate of AF are dynamic, but the time scales involved in trigger changes (generally related to altered Ca 2+ handling) versus substrate changes (related to conduction and refractoriness) differ according to the modulating factors involved ( Table 2 ). The vulnerable substrate maintaining AF is characterized by complex structural and electric alterations resulting in conduction abnormalities and short ERPs. 11 These are promoted by advancing age, as well as by changes in the environment, comorbidities and rhythm, with electric remodeling generally occurring within hours to days and structural remodeling taking weeks to months. The acute initiation of AF often occurs with a relatively rapid alteration in atrial electrophysiology although it may also emerge when a continuously varying parameter reaches a critical threshold. Ectopic activity, often from the pulmonary vein region and mediated by early afterdepolarizations or DADs, is a major AF-initiating mechanism. The atria are highly innervated by the autonomic nervous system (ANS), which modulates atrial electrophysiology on a beat-to-beat basis, positioning the ANS as a prime initiator of AF. 94 In agreement, all spontaneous paroxysmal atrial tachycardia and AF episodes in ambulatory dogs are preceded by changes in intrinsic cardiac nerve activity. 95 Acute norephineprhine-induced adrenergic activation also strikingly increases AF duration in mice via β 1 -adrenoceptor and α 1 -adrenoceptor-mediated signaling pathways. 96 Furthermore, long-term hyperactivity of the ANS, for example, with chronic sympathetic activation during HF, promotes cardiac remodeling, including structural remodeling, 1 desensitization of β-adrenoceptor signaling, and reduced expression of repolarizing K + currents, 97, 98 which have been implicated in ventricular arrhythmogenesis. Clinically, focal and rotational sources of AF in the LA identified through activation/phase mapping often colocalize with anatomic regions typical for important autonomic innervation in autopsy and animal studies. 99 Obstructive sleep apnea (OSA) has been implicated in the pathogenesis of AF. Contributing mechanisms include hypoxia, activation of the ANS and associated shortening of ERP, impaired left ventricular diastolic function, and atrial stretch because of atrial dilation. [100] [101] [102] Because AF onset often occurs during sleep apnea episodes, OSA seems to acutely enhance the risk of AF occurrence. 102 However, long-term repetitive OSA episodes cause reentry-promoting electric and structural remodeling, notably ERP shortening because of increased expression of atrial K + channels and conduction abnormalities related to connexin dysregulation and increased fibrosis. 103, 104 In agreement, patients with OSA have increased rotor prevalence. 105 Thus, OSA may both act as an acute trigger and promote development of a vulnerable substrate for reentry over days to weeks. Similarly, an interaction between gastroesophageal reflux disease (GERD) and AF has been proposed. 106 In some patients with GERD, AF is triggered within minutes by activities promoting gastroesophageal reflux (eg, intake of alcohol, cold water, or fatty food), suggesting GERD as a dynamic factor promoting AF.
Atrial electrophysiology is also affected by changes in serum electrolyte concentrations, which can vary on a timescale of minutes to hours, potentially triggering the initiation of AF, for example, during hemodialysis. 107 Extracellular potassium is a dynamic modulator of atrial electrophysiology: both hypokalemia 108 and hyperkalemia 109 have been associated with increased risk of AF. Similarly, magnesium supplementation after surgery has been associated with increased risk of postoperative AF. 109 The exact mechanisms through which electrolyte disturbances affect AF remain incompletely understood, but hypokalemia and hyponatremia both promote DADs in pulmonary veins. 110 Glucose ingestion, even without abnormal plasma glucose alterations, can also affect repolarization, 111 potentially influencing the reentrant substrate. Coronary artery disease is another established risk factor. Acute atrial ischemia causes pronounced conduction slowing within minutes to hours, promoting reentry-mediated AF in experimental studies, 112 which has been confirmed in recent clinical work. 113 The onset of AF has been described to show circadian variation, with peaks in the early morning and late afternoon/ early evening. 114, 115 Atrial ectopic activity also shows circadian variation, with a peak in the afternoon. 116 These data suggest a potential role for diurnal variations in autonomic tone, promoting AF-initiating ectopic activity. Others have reported a circadian variation in AF prevalence, but not onset of AF, 117 and persistent AF often begins at night, 118 suggesting that different subgroups of AF patients exhibit distinct temporal patterns. A further potential contributor is circadian variation in ion channel expression, 119, 120 an intriguing phenomenon of poorly understood importance. Inflammation is also a wellaccepted trigger for AF, operating on a timescale of hours to days. 121, 122 Clinically, markers of inflammation parallel the occurrence of postoperative AF, are elevated in patients with known AF and predict new-onset AF in some studies. [121] [122] [123] Similarly, animal studies have shown that reentrant circuits responsible for postoperative AF are dependent on the degree of inflammation, and that anti-inflammatory therapy decreases the incidence of postoperative AF and tachycardia-induced atrial remodeling. 122, 124 In the short term, inflammation may promote AF through oxidative stress and Ca
2+
-dependent triggered activity, whereas inflammation persisting for days to weeks promotes electric and structural remodeling. 122, 125 Finally, several dynamic factors operating on time scales of weeks to months have been implicated in AF, including a potential role for sex hormones, known to affect cardiac electrophysiology and arrhythmogenesis. 126 Serum estrogen concentrations are inversely correlated with the number and 127 and modulate the QT interval by controlling KCNH2 trafficking. 128 A seasonal variation in the incidence of AF, with lower incidence during summer and higher incidence in the fall or winter, has also been observed. 114, 129 Temperature-dependent changes in vascular resistance, resulting in altered blood pressure and ANS activity, as well as regulation of the circadian expression of ion channels in the presence of fewer daylight hours, have been suggested to be involved, 129 but the exact mechanisms remain unknown.
Taken together, AF is a moving target characterized by dynamic regulation of substrate and trigger across multiple timescales by different mechanisms (Figure 3) . Currently, our understanding of the dynamic factors that modulate AF risk is based on associations and clinical observations, with limited information about underlying mechanisms. The characterization of these dynamic modulators, their interactions, mechanistic basis, and relevance for diverse subgroups of patients with AF present a major translational goal. Here, we will focus primarily on the short-term modulators, operating over seconds to hours, which are poorly targeted by present AF therapy.
Opportunities Created by Recent Advances
The evidence on the important role of the ANS in the initiation of AF has resulted in the development of several therapeutic approaches based on ANS modulation. 94 For example, left and right stellate ganglia ablation suppresses premature atrial contractions and reduces episodes of paroxysmal AF in dogs, whereas low-level vagus nerve stimulation suppresses paroxysmal atrial tachyarrhythmias in ambulatory dogs. 94, 130 Vagus nerve stimulation also prevents rapid atrial pacinginduced ERP shortening and stimulates autonomic nerve remodeling, 131 thus potentially targeting both trigger and reentry substrate. Consistently, clinically detected focal and rotational sources of AF colocalize with regions of autonomic innervation, 99 and addition of ganglionated plexus ablation to standard pulmonary vein isolation increases the success rate compared with either approach alone. 132 However, other studies found that neither intraprocedural vagal reactions nor ANS modulation during cryoballoon pulmonary vein isolation predict subsequent freedom from AF. 133 Modulating ANS activity through renal artery denervation has also been shown to reduce the risk of AF in animal studies. 134 Although clinical evidence for the beneficial effect of renal denervation is limited, several clinical trials are currently ongoing. 134 In addition to ANS modulation via catheter-based or surgical procedures, recent studies have provided insight into the intracellular signaling cascades activated by ANS stimulation, for example, highlighting an important role for dysregulation of phosphatase-mediated dephosphorylation of ion channels and Ca 2+ -handling proteins in AF. 135 Nodal points in these signaling cascades, like inhibitor-1 of protein phosphatase type-1, may represent future pharmacological targets for AF treatment. 136 Endurance exercise training is associated with increased AF susceptibility. Inflammation, increased vagal tone because of augmented baroreflex responsiveness, and increased cardiomyocyte sensitivity to cholinergic stimulation, possibly because of RGS (regulator of G-protein signaling) protein downregulation, are important in endurance exercise-related AF promotion in animal models. 137, 138 Indeed, pharmacological inhibition of vagal activity can suppress exercise-induced increased AF susceptibility. 137 Moreover, inhibition of the inflammatory cytokine tumor necrosis factor-α with etanercept prevents atrial structural remodeling and AF vulnerability in response to exercise, without affecting the beneficial physiological changes. 138 Recent studies suggest that increased vagal tone, shortening ERP and promoting reentry, as well as local inflammation because of the proximity of the esophagus to the atrial myocardium, may be involved in the initiation of AF in patients with GERD. 106 Treatment with proton pump inhibitors reduces AF burden in some patients with GERD, suggesting that GERD treatment might represent a future component of integrated AF management. 106 Treatment of OSA with continuous positive airway pressure can acutely convert AF to sinus rhythm. 139 Continuous positive airway pressure produces more organized AF with fewer rotors 105 and reduces AF recurrence rates after pulmonary vein isolation. 140 Vagal triggers may also be involved in the AF-promoting effects of alcohol consumption. Figure 3 . Overview of the dynamic factors controlling the initiation, progression, and termination of atrial fibrillation (AF). The dynamic factors have been ordered according to the timescale of their operation (from seconds to years), with some factors that have both short-and long-term effects appearing twice. The dynamic factors are shown linked to the primary fundamental AF mechanisms that they are believed to influence (green for ectopic activity, blue for reentry-promoting electric remodeling, and orange for structural remodeling). ANS, autonomic nervous system; DAD, delayed afterdepolarization; EAD, early afterdepolarization; GERD; gastroesophageal reflux disease; and OSA, obstructive sleep apnea.
Prospects for Future Solutions
Dynamic factors may expose subclinical AF-promoting remodeling by raising a subthreshold substrate to the level needed to manifest AF, whether clinically or in experimental models. Clear interactions between a vulnerable substrate and dynamic factors needed for AF occurrence have been described. Sympathetic hyperactivity is associated with pacinginduced AF after acute atrial ischemia/infarction, 142 whereas chronic atrial ischemia/infarction creates both a vulnerable substrate and ANS-dependent dynamic triggers that together promote AF. 143 Likewise, obesity and acute OSA interact to promote AF in rats, whereby OSA increases LA diameter significantly more in obese than in lean rats and the combination produces greater AF susceptibility than either condition alone. 100 The requirement for both substrate and dynamic precipitators for the initiation of AF creates therapeutic opportunities. For example, renal sympathetic denervation reduces the incidence of new-onset AF after acute atrial ischemia in dogs by inhibiting cardiac sympathetic activity. 142 Likewise, noninvasive low-level transcutaneous electric stimulation of the auricular branch of the vagus nerve at the tragus suppresses shortening of atrial ERP and autonomic remodeling, preventing OSA-induced AF in dogs. 101 Translation of these insights from animal models to patients, in whom numerous dynamic factors interact with a much more complex substrate, remains challenging but potentially rewarding.
Advances in the understanding of the response of atrial cardiomyocytes to dynamic factors, such as the ANS, may pave the way for future pharmacological therapies. New approaches have been described that target regulatory subunits of phosphatases for the treatment of diabetes mellitus, hypertension, Parkinson disease, or drug addiction, suggesting potential novel opportunities to treat AF. 135 Inhibition of G i and G o proteins by nonviral plasmid vectors delivered to the posterior LA abrogates vagally induced AF in dogs. 144 Alterations in intracellular Ca 2+ seem to be a central downstream element for many of the dynamic factors. 11 For example, intracellular Ca 2+ acutely modulates atrial electrophysiology, promoting DADs and ectopic activity, can affect membrane levels of different ion channels within minutes by modulating trafficking, activate Ca 2+ -dependent signaling cascades that regulate posttranslational regulation of ion channels within minutes, and can exert transcriptional regulation over hours. 11, 145, 146 Thus, modulating dynamic intracellular Ca 2+ responses might hold promise for future therapeutic strategies aiming to prevent the dynamic initiation of AF. 147 A thorough understanding of the dynamic variations in AF mechanisms in patients will likely require longitudinal studies with repeated measurements. Moreover, the different time scales involved (Table 2) will necessitate almost continuous monitoring. In recent years, device-based AF detection using either implantable or hand-held devices has advanced significantly. 148 Although currently this technology is limited to the detection of the absence or presence of AF, it can already be used to obtain a better understanding of the dynamic factors underlying AF. A better insight into these dynamic factors might help to optimize opportunistic screening, increasing the cost effectiveness of this approach, and allowing better identification of patients with silent AF who would benefit from prophylactic therapy, like oral anticoagulation. 148 Technological advances will further reduce the size and costs of implantable loop recorders while simultaneously increasing storage capacity, battery life, and detection capabilities. These advances may make it possible to apply long-term monitoring to a much larger population of patients with AF and to use these devices beyond simple AF detection to infer patient-specific dynamic AF mechanisms. For example, heart rate variability parameters may provide an estimate of the sympathetic/vagal balance. Moreover, subcutaneous nerve activity, which can be estimated from a standard ECG, is more effective than heart rate variability in estimating the sympathetic/vagal balance and increased subcutaneous nerve activity occurs both at the onset and termination of AF. 149 The benefit of considering specific dynamic trigger-guided treatment is supported by the observation that nonrecommended treatment with β-adrenoceptor blockers resulted in aggravation of vagal AF. 150 Similarly, the identification of patients with primary sympathetic-triggered AF may help to guide better ablation strategies but is likely most effective in those in whom the dynamics of the ANS play an important role, potentially explaining why some clinical studies did not find a relationship between intraprocedural vagal reactions or ANS modulation and subsequent freedom from AF during cryoballoon pulmonary vein isolation.
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Achieving Atrial Targeting of Specific Molecular Arrhythmic Mechanisms
Translational Goal and Rationale
Extensive work during the past 20 years in small-and largeanimal AF models and tissue samples from patients with different forms of AF has led to the discovery of many novel molecular mechanisms that can act as new drug targets with the potential to improve AF management. Dysfunction in numerous atrial ion channels, along with altered function of many SR and sarcomeric proteins, abnormal atrial signaling, and numerous molecular targets involved in structural remodeling have been identified in extensive preclinical work (reviewed elsewhere 11, 135, [151] [152] [153] [154] ). Figure 4 is a schematic illustration summarizing the many functional and molecular motifs associated with AF along with their principal targets in cardiomyocytes and cardiac fibroblasts. Genetic variation contributes to AF susceptibility, with >30 AF-associated genome-wide association study loci reported to date. 155, 156 The majority of these loci are located in noncoding regions of the human genome, implicated in the transcriptional regulation of ion channel and ion channel-related proteins, components of atrial structure, including cardiopulmonary development, cardiac signaling, and transcription factors. Recent data also highlight the importance of epigenetic mechanisms, including DNA methylation, histone modification, and microRNA regulation. [157] [158] [159] Promising molecular targets in atrial cardiomyocytes include increased basal inward-rectifier K + current and constitutively active acetylcholine-activated inward-rectifier K + current, enhanced function of Ca
2+
-dependent small-conductance and two-pore domain K + -channels, altered SR Extensive work during the past 20 years has identified several molecular mechanisms in atrial cardiomyocytes and fibroblasts contributing to AF-promoting electric and structural atrial remodeling, which are potential molecular targets for AF therapy. Notable targets include ion channels involved in atrial electrophysiology (blue box), atrial Ca 2+ -handling and Ca 2+ -signaling (red box), microRNAs (miRs) inhibiting protein translation or promoting mRNA degradation (green boxes) of several targets (indicated in bold), transcription factors and gene regulatory networks (purple box), the components of the myofilaments (teal box), oxidative stress and altered metabolism (pink box), and inflammation (orange box). For all these components, there is a strong focus on targets with atrial-selective or atrial-predominant expression or atrial-selective effects (indicated with * -activated K + current; I to , transientoutward K + current; JAK/STAT, Janus kinase/signal transducers and activators of transcription; MAPK, mitogen-activated protein kinase; MEF2, myocyte enhancer factor-2; Mito, mitochondrion; MyBP-C, myosin-binding protein-C; MYL4, atrial light chain-1; NFAT, nuclear factor of activated T-cells; NLRP3, NACHT, LRR, and PYD domain binding protein-3; nNOS, neuronal nitric oxide synthase; PDGFR, platelet-derived growth factor receptor; PITX2, paired like homeodomain-2; PKC, protein kinase C; PLB, phospholamban; RLC, myosin regulatory light chain; ROS, reactive oxygen species; RyR2, ryanodine receptor channel type-2; SERCA2a, sarcoplasmic reticulum Ca 125 dysfunctional cardiomyocyte energy metabolism, 160 abnormal secretion of atrial natriuretic peptides, 161 and altered abundance of numerous microRNAs, among others. 11, 145, [152] [153] [154] 162, 163 Increased angiotensin-II, aldosterone, and transforming growth factor-β1 levels, abnormal mitogen-activated protein kinase (p38 and extracellular signal-regulated protein kinase), Smad and Janus kinase/signal transducers and activators of transcription 3 signaling, enhanced basal inward-rectifier K + current, transient receptor potential C3 and transient receptor potential M7 currents, and abnormal expression of a variety of microRNAs in atrial fibroblasts also offer exciting novel approaches to target atrial structural remodeling. Sarcolipin is an atrial-selective inhibitor of SERCA2a, and its abundance is reduced in patients with AF, likely contributing to dysregulated SERCA2a function. 11, 152, 164 The atrial-selective transcription factor PITX2 (paired like homeodomain-2), which is the closest gene to the strongest AF-associated single-nucleotide polymorphisms at 4q25, is the key modulator of a Tbx5-dependent gene regulatory network essential to maintain normal sinus rhythm. 165 This gene-network governs components controlling both the initiating trigger (via changes in RyR2 and SERCA2a) and the arrhythmogenic substrate (through alterations in connexin-43, desmoplakin, and Na + -channels) of AF and may offer unique opportunities to therapeutically target a nodal point of AF-promoting atrial remodeling.
Modulation of atrial-selective targets with small molecules has been attempted as an approach to achieve efficacy in the atria while minimizing extra-atrial adverse effects, particularly ventricular proarrhythmia. A range of such targets have been described. 166 Unfortunately, although atrial-selective K + -channels like acetylcholine-activated inward-rectifier K + current and ultrarapid delayed-rectifier K + current have been pursued for years, 167 recent clinical trials with selective inhibitors of these currents have been discontinued because of inadequate efficacy in the populations studied and extracardiac toxicity. Furthermore, imperfect selectivity can lead to serious off-target effects. For instance, although preclinical research shows a clear anti-AF effect and promising efficacy of CaMKII inhibition for AF promotion and persistence, 168 currently available CaMKII inhibitors, including inhibitory peptides and the small molecule KN-93, have limited efficacy and selectivity, making them unsuitable for clinical use. Besides issues with cell penetration, particularly of substrate competitors like inhibitory peptides, clinical application (and particularly chronic use) of CaMKII inhibitors must have no clinically relevant effects on α-and β-isoforms of CaMKII in the brain to avoid detrimental actions on memory and neuronal plasticity. 169 Optimization of the pharmacokinetic properties of small molecule CaMKII inhibitors will be required to minimize central nervous system penetration via the blood-brain barrier. Systemic CaMKII inhibition may also have negative effects on fertility. 170 Therefore, the success of CaMKII-dependent therapeutic strategies require the development of cardiac-specific CaMKII inhibitors. Of note, CaMKIIγ can substitute for CaMKIIδ in heart, 171 rendering it likely that successful CaMKII inhibition might require the inhibition of both CaMKIIδ and CaMKIIγ. The interest in small molecule drugs has waned, both because of past failures and because of the substantial development costs of bringing a new AAD to market. 24 Although AF ablation is successful for many patients, it becomes less successful as AF becomes longer standing and is plagued by failures and recurrences. Many ablation failures are related to atrial remodeling, whether before the procedure such that AF is too complex mechanistically to respond to present ablation approaches 51, 54, 57 or after ablation and causing long-term recurrence. 12, 140 Because of the limitations of currently available therapies, interest in novel molecular targets and new approaches providing more specific action has increased. These promise to offer an alternative and complement to ablation approaches and take advantage of rapidly advancing sciences and technologies. The main challenges to molecular therapeutics are the need to effectively and specifically intervene in maladaptive cardiac gene function and cell signaling without causing adverse consequences for other organ systems or biological networks.
Opportunities Created by Recent Advances
Intense research for the past 20 years has led to the identification of a wide range of promising molecular targets involved in AF pathophysiology (Figure 4) . Proof of principle has been obtained in animal models. For example, beneficial effects of transforming growth factor-β1 inhibition in atrial fibrosis were demonstrated with pirfenidone and tranilast in large-animal models of HF, hypertension, and atrial tachycardia. 172 Transient receptor potential C3 blockade prevents fibroblast activation and AF substrate development in a dog model of electrically maintained AF. 173 Janus kinase/signal transducers and activators of transcription inhibition reduces the profibrotic phenotype in canine fibroblasts in vitro while attenuating LA remodeling in postmyocardial infarction mice in vivo, suggesting that the Janus kinase/signal transducers and activators of transcription pathway contributes to LA fibrogenesis and might be a target for LA fibrosis prevention. 174 Atrial microRNA-21 knockdown suppresses atrial fibrosis and AF promotion in a rat myocardial infarction model 175 while inhibiting a STAT3 feedback loop in a sterile-pericarditis model, 176 implicating microRNA-21 as an important signaling molecule for the AF substrate and as a potential therapeutic target. 175 Knockdown of endogenous microRNA-26, mimicking its reduction in human AF, promoted AF in mice, and adenovirus-mediated overexpression of microRNA-26 reduced AF vulnerability. 177 However, although a wide range of individual miRNAs have been shown to play significant pathophysiological roles in AF, 159 ,163 AF-promoting pathologies can produce complex patterns of microRNA change. For example, HF alters the expression of a wide range of microRNAs, with different time courses, cell-type expression profiles, and chamber specificity. 178 A therapeutic strategy targeting a single microRNA is thus unlikely to be successful in AF.
There is extensive evidence for a role of sterile inflammation in AF. 122 Inflammatory mediators like myeloperoxidase seem central to angiotensin-induced AF and are overexpressed in patients with AF. 179 Mice with a mutation causing constitutive NLRP3 activation in cardiomyocytes show increased atrial ectopy, spontaneous AF, and pacing-induced AF vulnerability. 125 Atrial hypertrophy, abnormal diastolic SR Ca 2 + release, and ERP shortening are typical features of mice with constitutive NLRP3 activation. These data point to a specific novel role of cardiomyocyte NLRP3 activation in creating a vulnerable substrate for AF development by promoting both electric and structural remodeling.
Recent metabolomic and proteomic studies have shown changes in metabolic pathways in experimental and human AF, pointing to metabolic stress. 160 Abnormal mitochondrial function, compromised glucose utilization, and increased fatty acid oxidation, along with activated AMP-activated protein kinase, have been observed in atrial myocardium of patients with AF and have been validated in experimental AF paradigms. 160 Therapeutic modulation of selected metabolic pathways might permit new therapeutic opportunities for the management of AF.
Gene therapy approaches offer the promise of highly specific targeting of molecular pathways. The first gene therapy studied in AF used a dominant-negative mutation of the KCNH2 channel (KCNH2-G628S), which delayed repolarization, disrupted reentry, and terminated pacing-induced AF in pigs. 180 Subsequent work focused on transferring connexin-40 and -43 genes to improve conduction velocity and disrupt AFpromoting reentry: adenoviral gene transfer by electroporation 181 or gene-painting 182 of connexin-40 or -43 prevent burst pacing-induced and persistent AF in pigs. Preventing atrial apoptosis with small interfering RNA targeting caspase-3 suppressed apoptosis and delayed the onset of persistent AF without any effect on atrial fibrosis. 183 Increased transforming growth factor-β1 signaling is key for the formation of AFpromoting atrial fibrosis and structural remodeling. In dogs, injection of a plasmid expressing a kinase-deficient dominantnegative transforming growth factor-β type-II receptor in the posterior LA resulted in a significant decrease in HF-induced atrial fibrosis, conduction heterogeneity, and the complexity and duration of inducible AF. 184 Although these proof-of-concept studies show the feasibility of gene therapy for experimental AF, the lack of long-term transgene expression with these technologies strongly limits the clinical applicability of these approaches. Adeno-associated viral (AAV) vectors have been developed for cardiac gene therapy and hold the promise of producing long-lasting expression of relatively small genes in a cardiotropic fashion. 185 Their clinical applicability has been demonstrated, and they have been studied in randomized multicenter clinical trials 186 although they have yet to be established to have definitive therapeutic value.
Considering the diversity of the AF population and the complexity of the underlying pathophysiology, it is possible that the targeting of single molecular mechanisms will not translate into sufficient clinical benefit. Therapeutic targeting of proteins involved in nodal points and regulatory networks might be a more promising approach. Modulation of the renin-angiotensin-aldosterone system has been suggested as upstream therapy targeting atrial remodeling in AF for many years. Despite conflicting results with renin-angiotensin-aldosterone system inhibitors, meta-analyses suggest that renin-angiotensin-aldosterone system inhibition prevents recurrent AF and is effective for prevention of AF development in essential hypertension. 187, 188 A recently identified Tbx5-driven network is repressed by PITX2, with PITX2 being directly activated by Tbx5. The latter requires precise fine-tuning because decreases in network stimulatory Tbx5 and decreases in network inhibitory PITX2 both increase AF susceptibility despite the fact that they cause opposite effects on expression of downstream network components. 165 These findings are in line with the demonstration that the mRNA levels of PITX2 strongly vary in the LA of patients with AF. 189 Both increased mRNA 190 and decreased mRNA of PITX2 have been shown in association with PITX2 promoter hypermethylation. 157, 191 Lower PITX2 expression-levels in mice, mimicking the situation in some patients with AF, associate with more depolarized membrane potential, leading to postrepolarization refractoriness, which increases the efficacy of class I AADs. 189 However, PITX2 overexpression has also been associated with increased risk of AF. Clearly, precise targeting of this network is challenging, and it remains unclear whether PITX2 mediates the association between genetic variants at 4q25 and AF. 192 The loci with the strongest association with AF are 150.000 bases upstream of PITX2, and the association between 4q25 variants and PITX2 levels, atrial dilatation, or catheter ablation outcomes is modest, 193 suggesting that other mechanisms may be involved. Recent work has identified a long noncoding RNA located adjacent to PITX2 that regulates PITX2c levels, 194 but more work is needed to understand the mechanisms controlling the gene regulatory networks that modulate AF risk.
Prospects for Future Solutions
The presently-identified genetic loci still explain a small minority of AF heritability, pointing to the possibility that a large proportion of heritability results from gene-environment and gene-gene interactions. Although a recent study did not identify significant interactions between the known AF susceptibility genes, 195 increases in sample size together with improved genotyping are expected to facilitate the identification of important gene-gene interactions associated with AF. Genetic interactions of these loci with age, sex, and comorbidities likely also exist because AF pathophysiology in individuals of European descent seems to differ according to age, 196 further complicating the detection of AF susceptibility in the individual. The identification of important gene-gene interactions with clear impact on AF pathophysiology and management might open new avenues for gene therapy in AF.
A major challenge to molecular therapeutics is finding a way to modify molecular pathways effectively, safely, and specifically in human atria. Recent advances in AAV-based vector technology and targeted delivery techniques allow for efficient, safe, and long-term gene transfer to the heart. For cardiac gene transfer, 3 AAV serotypes (AAV1, AAV6, and AAV9) have emerged as the most promising AAV variants. AAVs are ideal for gene therapy because they are nonpathogenic, minimally immunogenic, of small size allowing delivery to the myocardium via coronary artery infusion, and are able to induce long-term (up to years) transgene expression in cardiomyocytes after single delivery. 197 These advantages of AAVs compared with adeno-and lentiviruses have already allowed AAVs to enter the clinical setting to transfer SERCA2a as a potential therapeutic approach for patients with HF. Reduced expression of SERCA2a is an important contributor to impaired contractility and arrhythmogenesis in HF. 198 Although the CUPID (Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease) phase-1 trial using a recombinant AAV1 vector (AAV1.SERCA2a) provided a positive signal, 198 the CUPID2 phase-2 study failed to confirm benefits from AAV1. SERCA2a gene transfer in patients with HF . 186 Despite the negative outcome, the trial did demonstrate the feasibility of cardiac gene transfer via AAVs in man.
Although offering several advantages, the use of AAVs for cardiac gene delivery in patients also has important potential limitations. Humans can harbor pre-existing neutralizing antibodies against AAVs, 199 which prevent efficient gene transduction and their presence is an exclusion criterion in all AAV gene therapy trials. In addition, species-dependent differences in virus tropism exist, and the current knowledge about cardiac tropism of AAVs in humans is limited. Finally, not all currently available AAV delivery methods for cardiac gene therapy can be applied to humans. Molecular cardiac surgery with recirculating delivery is possible but is highly invasive and can only be applied to patients undergoing onpump coronary bypass surgery or valve replacement. Because of its minimal invasiveness, antegrade intracoronary injection is the most frequent delivery method used for humans. However, in the CUPID trial, in which this delivery method was used, intracoronary administration of AAV1 resulted in insufficient cardiomyocyte uptake. Simple intravenous injection of cardiotropic AAVs can transfer sufficient quantities of selected genes to produce long-lasting reversal of genetic arrhythmia syndromes in animal models. 200, 201 It remains to be seen whether this approach will be feasible in man.
Another potential approach is gene knockdown with the use of RNA interference technology. A proprotein convertase subtilin-kexin type-9-targeting synthetic small interfering RNA dramatically reduced low-density lipoprotein cholesterol for >3 months in patients after a single subcutaneous dose, 202 indicating the feasibility of this method for cardiovascular therapeutics. Inclisiran, the construct used, is chemically modified to increase its stability and is conjugated to N-acetylgalactosamine carbohydrates that bind to hepatocytespecific asialoglycoprotein receptors. For this technology to be useful in heart disease, the interfering molecule would need to be conjugated to a chemical structure that allows cardiomyocyte-specific uptake. Although this is certainly challenging to develop, it could provide effective therapeutics by delivering specific molecular therapeutics for a range of cardiac conditions.
Monoclonal antibodies are also being applied for molecular cardiovascular therapeutics. Two fully-human monoclonal antibodies to proprotein convertase subtilin-kexin type-9, evolocumab and alirocumab, are being used extensively to treat dyslipidemias. Similarly, a monoclonal antibody to interleukin-1β, canakinumab, has recently been shown to prevent cardiovascular events in patients with myocardial infarction and an elevated C-reactive protein level. 203 The effects of parenteral monoclonal antibodies are potent and long lasting and could theoretically be used to target any of the molecular pathways shown in Figure 4 that have epitopes accessible to the extracellular space.
Another novel approach of potential interest is to develop molecules that specifically interact with intracellular targets. Recent work has shown that G-protein-coupled receptor systems can be localized to cardiac-cell nuclei, where they specifically modulate gene expression in response to intracrine signaling. 204 Intracellular angiotensin-II signaling in atrial fibroblasts specifically regulates collagen secretion and fibroblast proliferation and is upregulated in AF-promoting structural remodeling caused by HF. 205 Recent technological advances have allowed for the development of prodrug caged ligands that are activated intracellularly and specifically block intracrine signaling, allowing for novel therapeutic approaches that may be uniquely effective for new forms of cardiovascular molecular therapeutics.
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Clarifying the Response of the Arrhythmogenic Substrate to Interventions
Translational Goal and Rationale
The main clinical criterion for the effectiveness of new drug therapies for AF has been randomized double-blinded assessment in large-scale clinical trials. 5, 6 Appropriately-powered randomized trials are, and will remain, the appropriate definitive test of the effectiveness of any intervention. However, they are extremely costly and challenging to execute. For innovative therapeutics, there is a need for proof-of-concept studies before moving to large-scale clinical trials, particularly when any individual approach has a limited likelihood of succeeding. In addition, confirmation of the link between a hypothesized mechanistic target and the arrhythmia requires demonstration that the target has indeed been modified, along with correlation between the modified target and the clinical response.
An instructive (though unfortunately negative) example is the targeting of premature ventricular complexes (PVCs) for the prevention of sudden cardiac death. Extensive basic and clinical research suggested a mechanistic link between them, with sudden cardiac death thought to be because of PVCs inducing fatal ventricular tachyarrhythmias by occurring in the vulnerable phase of the cardiac cycle. Extensive effort was expended to develop orally-administered drugs that eliminated PVCs, resulting in the successful demonstration that such agents were extremely potent in suppressing PVCs on 24-hour monitoring. 207, 208 However, a well-designed randomized trial subsequently showed that while these agents effectively suppressed PVCs, they paradoxically increased the risk of sudden cardiac death and associated mortality. 209 This series of studies dramatically showed that the widely-held theory of sudden cardiac death pathophysiology was in fact invalid and that its therapeutic targeting was doomed.
The translational approach to developing new AF therapies discussed here assumes that the pathophysiological links described are valid and applicable in human AF and that targeting them will suppress AF and improve AF-related adverse clinical events. The new technologies described above allow for the direct assessment of the response to interventions of substrates thought to underlie AF in man. This has to date been done to only a limited extent. For example, a wide range of modifiable risk factors like obesity, sleep apnea, hypertension, and diabetes mellitus have been shown to promote AF and to cause arrhythmogenic atrial remodeling in animal models; furthermore, there is evidence that their control may prevent AF. 102 However, changes in the atrial substrate with lifestyle/risk factor intervention have not been shown in humans. Analysis of the relationship between substrate response and outcomes would help in confirming the role of the substrate in AF pathophysiology. Furthermore, it would allow for the assessment of interventions designed to target these substrates before engaging in potentially costly large-scale clinical trials that might unnecessarily expose patients to ineffective therapies.
Opportunities Created by Recent Advances
Recent technological developments described above now allow for the assessment of many putative AF substrates in vivo in humans. Some have already been applied to study links between putative substrates and the therapeutic response.
For example, FIRM mapping allows for the identification of putative focal and reentrant sources contributing to AF maintenance, followed by their targeted ablation. The correlation between changes in putative sources and clinical outcomes should allow for circumstantial evidence of their role in maintaining the arrhythmia. To some extent, this has been accomplished. Targeting of these sources has been shown in a multicenter trial to produce better outcomes than conventional ablation 39, 210 although contradictory results have been reported by other trials. 34 Evidence has also been provided that elimination of such focal and rotational sources explains the successful outcome of AF ablations using other strategies. 211 The supportive evidence has been sufficient (despite considerable clinical skepticism) that the FIRM approach is now under extensive investigation in multicenter randomized trials. 34 These and future correlative studies will solidify the link between the postulated AF-maintaining mechanisms and the arrhythmia. The invasive nature of FIRM mapping limits its value for testing novel therapeutic measures other than those (like ablation) that intrinsically require an invasive approach.
ECGi is noninvasive and also provides information about putative AF-maintaining mechanisms. 61 However, rather than the stable rotors noted by FIRM, the application of ECGi has shown short-lived unstable drivers 37 that tend to be localized at the border between zones with intense versus less severe fibrosis. 38 Because ECGi is performed 24 hours in advance of ablation procedures, the correlation between the mapped sources and the procedure is less direct than for FIRM. An advantage of ECGi is that it can be applied consecutively to study the evolution of the putative arrhythmic substrate. Observational studies suggest that patients with longer duration AF have larger numbers of drivers, particularly rotational, in more atrial areas, and that the increased complexity of drivers is associated with poorer ablation outcomes. 212 Longitudinal comparisons of ECGi results in patients pre-ablation versus at various time points afterward, as well as in patients with AF who are not subjected to ablation, could provide a wealth of information about the natural history of the putative mechanistic substrate, as well as the mechanistic determinants of ablation success versus failure.
LGE-MRI similarly provides noninvasive information about the AF substrate in terms of the atrial fibrosis believed to play a central role. The application of LGE-MRI has shown the correlations with outcomes expected if fibrosis plays a significant role. For example, the extent of baseline fibrosis and, more importantly, residual fibrosis not covered by ablationinduced scar is associated with AF recurrence after ablation. 213 The use of LGE-MRI defined fibrosis data to create patientspecific simulations of arrhythmia-maintaining rotor activity is a further application of the notion that fibrosis plays a central role in the AF-maintaining substrate 79 and is being directly applied to guide ablation procedures. A still more direct application of LGE-MRI is the direct targeting of fibrotic regions for AF ablation: the DECAAFII study (Efficacy of DE-MRIGuided Ablation vs Conventional Catheter Ablation of Atrial Fibrillation II; NCT02529319; final data entry expected July 2020) is randomizing patients to pulmonary vein isolation alone versus pulmonary vein isolation plus fibrosis-targeted ablation.
Prospects for Future Solutions
Noninvasive indices, like ECGi and LGE-MRI, could be used to assess the effectiveness of agents designed to modulate novel molecular targets on intermediate end points. For example, until now, the only way to evaluate the action of an intervention designed to prevent AF by suppressing atrial fibrosis was to examine its ability to prevent AF recurrence. If the intervention failed, it was not clear whether it failed because it did not influence fibrosis or whether fibrosis was not in fact an important contributor to the AF substrate in the patients treated.
LGE-MRI could presumably be used in smaller proof-of-principle studies to show that an antifibrotic approach really achieves its intended purpose or in AF intervention studies to follow changes in fibrous tissue content to confirm or refute the role of fibrosis changes in the observed outcomes. Similarly, sequential ECGi could be used to assess whether a novel AAD, designed to target reentry or ectopic activity, is indeed producing the mechanistic changes for which it is designed.
Other technical advances discussed above could be similarly applied. Photoacoustic imaging might someday be directly applied to evaluate the role of intracellular Ca 2+ or reactive oxygen species changes and of maneuvers targeting them, in AF occurrence. Techniques that track cellular metabolic state, like Raman spectroscopy, could be used to assess the effectiveness of therapies designed to reverse AF-related metabolic abnormalities.
All of the novel measurement methods discussed above could provide valuable insights into the effects of primary prevention approaches. For example, to what extent does control of obesity, hypertension, OSA, diabetes mellitus, cigarette smoking, and other risk factors affect atrial fibrosis, AF-maintaining rotors and ectopic sources, atrial metabolism, and reactive oxygen species production, etc? The information obtained would be extremely valuable in better understanding the pathophysiology of AF specifically in individuals, as well as in the AF population in general.
An ultimate goal would be to obtain a detailed patient-specific portrait of the operative pathophysiological mechanisms, target therapy toward them, and test the effectiveness of this personalized approach in a prospective way.
Summary and Conclusions
Here, we have considered several translational challenges to improving AF management. Their inter-relationships are summarized in Figure 5 . Even though each of them presents a complex of important and worthy endeavors, their contributions to improving AF management are inter-related. A common starting point is the definition of actionable patientspecific arrhythmia mechanisms in vivo, primarily by improved noninvasive imaging of tissue activation and substrates. Pathophysiological studies (in animal models, human tissue samples, and in silico systems) identify targetable dynamic modulators and molecular mechanisms, and technological advances provide safe and effective therapeutic approaches to target them. Finally, in vivo imaging and pathophysiological studies in preclinical and clinical model systems confirm the response of the substrate and its relationship to clinical effects. The ultimate goal of this paradigm is to produce effective novel AF management approaches to be tested in appropriately designed randomized clinical trials. These studies should allow for improvements in our understanding of the fundamental mechanisms controlling AF occurrence and ultimately result in improved AF management. 
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